Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2013-12-04 Investor Presentation
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Presentation of HIV Data at HIV Persistence Meeting 3 pages 280.8KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial data related to the antiviral efficacy of BIT225 in HIV-1 infected patients. It includes study design, results, pharmacokinetics, and conclusions from a Phase 1b/2a clinical trial. The text mentions a presentation at an international meeting and includes detailed scientific data and analysis rather than a brief announcement or summary. There is no indication that this is an earnings release, annual report, or regulatory filing. The content is consistent with an Investor Presentation (IP) as it focuses on clinical trial results, drug development progress, and potential market impact for investors. The document length (15,000 characters) and detailed data support this classification rather than a short announcement or report publication notice.
2013-12-04 English
Independent Research Validates Biotron HCV Drug Candidate 2 pages 56.4KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (2 pages) dated 27 November 2013 from Biotron Limited to the ASX. It discusses independent research validating their drug candidate BIT225 for Hepatitis C virus, summarizing scientific findings and clinical trial progress. There are no financial statements, regulatory certifications, or detailed financial data. The document is informational and promotional about research validation and clinical trial results, not a formal financial report or regulatory filing. It is also under 5,000 characters and does not contain or attach a full report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement to the stock exchange about company developments that do not fit other specific categories.
2013-11-26 English
Ethics Approval for Three Month HCV Trial 4 pages 61.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Biotron Limited regarding ethics approval for a new clinical trial study of their drug BIT225 for Hepatitis C Virus (HCV). It includes a trial synopsis, study design, objectives, and background information about the company and drug development. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is not a report of financial results, audit, or management discussion. It is a regulatory announcement about a clinical trial approval and study commencement, which does not fit into financial report categories. It is not a short announcement of a report publication either. The content is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement related to company operations and clinical trial progress.
2013-11-20 English
Presentation to Annual General Meeting 26 pages 3.0MB
AGM Information Classification · 100% confidence The document is a detailed PowerPoint presentation intended for delivery at an Annual General Meeting (AGM) held on 8 November 2013, as explicitly stated in the letter and the document title. It contains extensive information about the company's clinical trials, drug development progress, market context, and strategic outlook, which are typical contents of an investor or shareholder presentation at an AGM. The document is not a full annual report, audit report, or earnings release, but rather a presentation to shareholders at the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is the presentation itself, not just an announcement of a report.
2013-11-07 English
Results of Meeting 2 pages 30.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a communication dated 8 November 2013 addressed to the ASX Limited, reporting the results of the Annual General Meeting (AGM) held on that day. It includes voting results for resolutions put to shareholders, including re-election of directors and adoption of the remuneration report. It also contains the Notice of Annual General Meeting with agenda items and resolutions to be considered. The document is short (2439 characters) and primarily reports the voting outcomes and meeting notice rather than providing the full annual report or financial statements. Therefore, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-11-07 English
Final Director's Interest Notice 3 pages 26.5KB
Board/Management Information Classification · 100% confidence The document is a notification to the ASX regarding a director change following an Annual General Meeting. It specifically states that Bruce Hundermark has not been re-elected as a director and includes an Appendix 3Z, which is a Final Director's Interest Notice. The content focuses on director changes and related securities interests, with no financial statements or report data. The document length is short (3077 characters) and is a formal announcement of a director change, not a full report or financial filing. Therefore, it fits the category of Board/Management Information (MANG).
2013-11-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.